Observational studyProstate cancer and prostatic diseases2023
Gut environment changes due to androgen deprivation therapy in patients with prostate cancer.
Observational study in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment.Prostate cancer and prostatic diseases · 2026Pooled it
- Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review).International journal of molecular medicine · 2026Review
- Gut microbiota and its metabolites: Key factors of drug resistance in the treatment of advanced prostate cancer (Review).Molecular medicine reports · 2026Review
- Mass spectrometry-based metabolomics for studying gut microbiota-derived metabolites in biological samples.Journal of food and drug analysis · 2026Review
- The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities.Cancers · 2026Review
- Probiotics as Microbiome Modulators in Male Infertility: Rethinking Dysbiosis Across the Gut-Testis Axis.Journal of personalized medicine · 2026Review
- Testosterone deficiency synergistically exacerbates fructose-induced hepatic steatosis through gut microbiota and pyruvate in mice.American journal of physiology. Endocrinology and metabolism · 2026Article
- The Biosocial Microbiome: Gender Identity, Geography, and Mucosal Microbial Phenotypes.Research square · 2026Article
- Gut-prostate axis in prostate cancer: microbiome signatures, mechanistic insights, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Quality of life and supportive care needs in prostate cancer: the impact of treatment received and care service utilization among Māori and non-Māori patients in New Zealand.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Reprogramming prostate cancer through the microbiome.Frontiers in medicine · 2025Review
- Androgen Deprivation Therapy and the Risk of Newly Developed Dry Eye Syndrome in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in the Republic of Korea.Journal of clinical medicine · 2024Article
- Review
- Review
- Microbiome Dysbiosis Is Associated with Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer.International journal of molecular sciences · 2024Article
- Gut microbiome: a novel preventive and therapeutic target for prostatic disease.Frontiers in cellular and infection microbiology · 2024Review
- A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer.Biomedicines · 2023Review
- The human microbiome links to prostate cancer risk and treatment (Review).Oncology reports · 2023Review
- [Latest Findings on the Effect of Gastrointestinal Microecology Remodeling of Tumor Microenvironment on Tumor Stemness].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is estimated that by 2040 there will be 1,017,712 new cases of prostate cancer worldwide. Androgen deprivation therapy (ADT) is widely used as a treatment option for all disease stages. ADT, and the resulting decline in androgen levels, may indirectly affect gut microbiota. Factors affecting gut microbiota are wide-ranging; however, literature is scarce on the effects of ADT on gut microbiota and metabolome profiles in patients with prostate cancer.
methodsTo study the changes of gut microbiome by ADT, this 24-week observational study investigated the relationship between testosterone levels and changes in gut microbiota in Japanese patients with prostate cancer undergoing ADT. Sequential faecal samples were collected 1 and 2 weeks before ADT, and 1, 4, 12, and 24 weeks after ADT. Blood samples were collected at almost the same times. Bacterial 16 S rRNA gene-based microbiome analyses and capillary electrophoresis-time-of-flight mass spectrometry-based metabolome analyses were performed.
resultsIn total, 23 patients completed the study. The α- and ß-diversity of gut microbiota decreased significantly at 24 weeks after ADT (p = 0.017, p < 0.001, respectively). Relative abundances of Proteobacteria, Gammaproteobacteria, Pseudomonadales, Pseudomonas, and concentrations of urea, lactate, butyrate, 2-hydroxyisobutyrate and S-adenosylmethionine changed significantly after ADT (p < 0.05). There was a significant positive correlation between the abundance of Proteobacteria, a known indicator of dysbiosis, and the concentration of lactate (R = 0.49, p < 0.01).
conclusionsThe decline in testosterone levels resulted in detrimental changes in gut microbiota. This dysbiosis may contribute to an increase in frailty and an increased risk of adverse outcomes in patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.